Shuji Matsumoto1, Megumi Shimodozono, Ryuji Miyata, Kazumi Kawahira. 1. Department of Rehabilitation and Physical Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kirishima City, Kagoshima, Japan. shushu@m.kufm.kagoshima-u.co.jp
Abstract
PRIMARY OBJECTIVE: Cilostazol is an antiplatelet agent that inhibits phosphodiesterase III in platelets and the vascular endothelium. We assessed the effects of cilostazol on human cerebral hemodynamics and rehabilitation outcomes. RESEARCH DESIGN: Prospective, consecutive, observational trial with pretreatment and posttreatment evaluations. EXPERIMENTAL INTERVENTIONS: Cilostazol (200 mg/day) administered for 8 weeks. METHODS AND PROCEDURES: Cerebral blood flow at rest, cerebrovascular reserve capacity, and rehabilitation outcomes (Brunnstrom stage, Barthel index score, modified Rankin Scale score, and Mini-Mental State Examination score) were measured in 104 poststroke patients with an average age ± standard deviation of 60.8 ± 9.2 years. MAIN OUTCOMES AND RESULTS: The cerebral blood flow increased by 23.8% on the affected side of the brain and by 16.9% on the nonaffected side. The cerebrovascular reserve capacity increased by 19.0% on the affected side of the brain and by 13.3% on the nonaffected side. Improvements were observed in the Brunnstrom stage, Barthel index score, modified Rankin Scale score, and Mini-Mental State Examination score. CONCLUSIONS: Cilostazol appeared to have beneficial effects in poststroke patients with cerebral ischemia and might improve cerebral circulation and rehabilitation outcome.
PRIMARY OBJECTIVE:Cilostazol is an antiplatelet agent that inhibits phosphodiesterase III in platelets and the vascular endothelium. We assessed the effects of cilostazol on human cerebral hemodynamics and rehabilitation outcomes. RESEARCH DESIGN: Prospective, consecutive, observational trial with pretreatment and posttreatment evaluations. EXPERIMENTAL INTERVENTIONS:Cilostazol (200 mg/day) administered for 8 weeks. METHODS AND PROCEDURES: Cerebral blood flow at rest, cerebrovascular reserve capacity, and rehabilitation outcomes (Brunnstrom stage, Barthel index score, modified Rankin Scale score, and Mini-Mental State Examination score) were measured in 104 poststroke patients with an average age ± standard deviation of 60.8 ± 9.2 years. MAIN OUTCOMES AND RESULTS: The cerebral blood flow increased by 23.8% on the affected side of the brain and by 16.9% on the nonaffected side. The cerebrovascular reserve capacity increased by 19.0% on the affected side of the brain and by 13.3% on the nonaffected side. Improvements were observed in the Brunnstrom stage, Barthel index score, modified Rankin Scale score, and Mini-Mental State Examination score. CONCLUSIONS:Cilostazol appeared to have beneficial effects in poststroke patients with cerebral ischemia and might improve cerebral circulation and rehabilitation outcome.
Authors: Adam de Havenon; Kevin N Sheth; Tracy E Madsen; Karen C Johnston; Tanya N Turan; Kazunori Toyoda; Jordan J Elm; Joanna M Wardlaw; S Claiborne Johnston; Olajide A Williams; Ashkan Shoamanesh; Maarten G Lansberg Journal: Stroke Date: 2021-09-14 Impact factor: 10.170